3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study
Johan Hansson(Karolinska Institutet), Axel Hauschild(University Hospital Schleswig-Holstein), A. Fittipaldo(Roche (United Kingdom)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), R. Kuntsfeld, Lisa Licitra(University of Milan), Richard Dummer, Thomas Jouary(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicole Basset‐Séguin(Université Paris Cité), Kate Fife(Addenbrooke's Hospital), Jean‐Jacques Grob(Aix-Marseille Université), B. Guillot(Université de Montpellier), D. Scott Ernst, Laurent Mortier, Nicole Meyer(Université Toulouse III - Paul Sabatier), Yeun Mi Yim(Genesys (United States)), Brigitte Dréno(Nantes Université), Karen Bartley(Genesys (United States)), Sophie Williams
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k